BMO Capital Reiterates Outperform Rating on TrueBlue (TBI)

BMO Capital analyst Jeffrey Silber reiterated an Outperform rating and $13.00 price target on TrueBlue (NYSE: TBI).

The analyst commented, "We recently held an NDR for TBI, where we came away more confident in its prospects once the sector recovers. Light industrial staffing typically leads a sector recovery; that should reoccur, potentially boosted by secular growth drivers (e.g., reshoring). TBI's RPO business has historically been its fastest-growing and highest margin—something that should also continue. Margin expansion may be boosted by recent cost management actions; management stating that incremental margins could be at the high-end of historical ranges. We believe its current valuation offers an attractive entry point."

For an analyst ratings summary and ratings history on TrueBlue click here. For more ratings news on TrueBlue click here.

Shares of TrueBlue closed at $10.18 yesterday.

You May Also Be Interested In